Orders for its new treatment modalities boosted sales revenues for medical isotope developer IsoRay Medical of Richland, WA, in the second quarter of fiscal year 2010 (end-December 31).
Sales increased 3% to $1.4 million, compared with $1.3 million in the second quarter of fiscal 2009. Revenues during the quarter were primarily generated through the sales of Proxcelan cesium-131 seeds for the treatment of prostate cancer.
The company's net loss decreased 42% to $950,000 in the second quarter, compared with a net loss of $1.6 million in the same quarter a year ago.
For the six-month period, revenues remained steady at $2.8 million in fiscal year 2010, compared with $2.8 million in the first half of fiscal 2009. The company's net loss lessened to $1.8 million for the first six months of fiscal 2010, compared with a net loss of $3.4 million in the same period of fiscal 2009.
Related Reading
IsoRay adds VP, January 27, 2010
IsoRay targets Canada research, January 25, 2010
IsoRay touts cesium-131 colorectal treatment, January 21, 2010
IsoRay inks distribution deal with Oncura, December 4, 2009
IsoRay adds Canadian distributor, November 18, 2009
Copyright © 2010 AuntMinnie.com
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
